Oxford Nanopore Technologies (ONT) Bernstein Annual Pan-European Strategic Decisions Conference summary

Key technology and market positioning

• Nanopore sequencing enables rapid, real-time, high-definition DNA and RNA analysis, offering both long and short read capabilities for diverse applications.

• The technology is more affordable and accessible than traditional sequencing, with devices ranging from handheld to high-throughput systems.

• Nanopore sequencing is uniquely positioned to address the 'dark genome,' providing insights into complex diseases and structural variants.

• The company is expanding beyond research into clinical, biopharma, and industrial markets, leveraging its direct RNA sequencing and real-time analysis.

• Over 13,000 publications validate the platform, supporting its adoption in global genomics and multi-omic research.

Business model and customer segments

• Operates both OpEx (leasing, consumables) and CapEx (device sales) models, adapting to customer preferences in research, clinical, and industrial sectors.

• Devices are significantly cheaper than competitors, enabling broader adoption and immediate profitability on placements.

• 70% of revenue comes from research, 9% from clinical, 9% from biopharma, and 12% from applied/industrial markets.

• Biopharma and applied markets are expected to drive above 30% annual growth through 2027, with direct RNA and biologics QC as key differentiators.

• The company is open to both business models and expects increasing CapEx demand from biopharma and industrial clients.

Strategic partnerships and global initiatives

• Collaborating with bioMérieux to develop affordable, comprehensive TB drug resistance tests for low- and middle-income countries, with plans for broader infectious disease applications.

• Singapore is highlighted as a leader in integrating genomics into healthcare, using population-wide sequencing for predictive and preventive medicine.

• The technology is being trialed in global public health labs, with successful pilots in TB, and potential for other diseases like gonorrhea.

• Partnerships are strategic and focused to avoid overextension, with potential for expansion as initial projects mature.

• The platform supports biosurveillance and environmental monitoring, with early adoption in pandemic response and antimicrobial resistance tracking.